[go: up one dir, main page]

WO1992004048A3 - Inhibition of metastasis potential and invasiveness by oligosaccharides or oligosaccharide antigens or antibodies - Google Patents

Inhibition of metastasis potential and invasiveness by oligosaccharides or oligosaccharide antigens or antibodies Download PDF

Info

Publication number
WO1992004048A3
WO1992004048A3 PCT/US1991/006202 US9106202W WO9204048A3 WO 1992004048 A3 WO1992004048 A3 WO 1992004048A3 US 9106202 W US9106202 W US 9106202W WO 9204048 A3 WO9204048 A3 WO 9204048A3
Authority
WO
WIPO (PCT)
Prior art keywords
oligosaccharides
antigens
metastasis potential
antibodies
invasiveness
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1991/006202
Other languages
French (fr)
Other versions
WO1992004048A2 (en
Inventor
Tatsushi Toyokuni
Sen-Itiroh Hakomori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomembrane Institute
Original Assignee
Biomembrane Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomembrane Institute filed Critical Biomembrane Institute
Priority to AU86677/91A priority Critical patent/AU659808B2/en
Publication of WO1992004048A2 publication Critical patent/WO1992004048A2/en
Publication of WO1992004048A3 publication Critical patent/WO1992004048A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

Agents and methods for inhibiting metastasis potential of tumor cells are provided. Metastasis potential of tumor cells may be inhibited by an agent selected from the group consisting of (a) tumor-associated carbohydrate antigens (TACAs) that exhibit differential prognostic significance, (b) antibodies that specifically bind to these antigens, (c) oligosaccharide components of these antigens, and (d) conjugates of these antigens or oligosaccharides, wherein the agent inhibits the metastasis potential of the preparation. Additional oligosaccharides for use within the methods and compositions provided herein include lactose and lactose derivatives. The present invention also discloses conjugates comprising oligosaccharides and poly(ethylene glycol).
PCT/US1991/006202 1990-08-30 1991-08-29 Inhibition of metastasis potential and invasiveness by oligosaccharides or oligosaccharide antigens or antibodies Ceased WO1992004048A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU86677/91A AU659808B2 (en) 1990-08-30 1991-08-29 Inhibition of metastasis potential and invasiveness by oligosaccharides or oligosaccharide antigens or antibodies

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US57553990A 1990-08-30 1990-08-30
US575,539 1990-08-30
US72498391A 1991-07-02 1991-07-02
US724,983 1991-07-02

Publications (2)

Publication Number Publication Date
WO1992004048A2 WO1992004048A2 (en) 1992-03-19
WO1992004048A3 true WO1992004048A3 (en) 1992-10-01

Family

ID=27076723

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/006202 Ceased WO1992004048A2 (en) 1990-08-30 1991-08-29 Inhibition of metastasis potential and invasiveness by oligosaccharides or oligosaccharide antigens or antibodies

Country Status (5)

Country Link
EP (1) EP0546122A1 (en)
JP (1) JPH06501008A (en)
AU (1) AU659808B2 (en)
CA (1) CA2089375A1 (en)
WO (1) WO1992004048A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
EP0544898A1 (en) * 1991-06-26 1993-06-09 The Biomembrane Institute Early diagnosis of lung cancer using anti-carbohydrate antibody combinations
US5639737A (en) * 1991-11-04 1997-06-17 Co Enzyme Technology Ltd. Method and compositions for treating malignant tumors and inhibiting growth and metastases of malignant tumors
AU677789B2 (en) * 1992-07-02 1997-05-08 Collagen Corporation Biocompatible polymer conjugates
DE4236237A1 (en) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, their preparation and use as medicines
NZ304991A (en) * 1995-04-14 2000-02-28 Kazunori Kataoka Use of polyoxyethylene having a sugar on one end and a different functional group on the other end as a carrier for the production of medicaments
US6841543B1 (en) 1996-01-31 2005-01-11 President And Fellows Of Harvard College Methods of inhibiting production of T helper type 2 cytokines in human immune cells

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3228233A1 (en) * 1982-07-28 1984-02-02 Wolfgang Dr. 6500 Mainz Dippold The use of the antibody R-24 and method for the inhibition of the cell growth of melanoma cells
EP0249008A2 (en) * 1986-05-09 1987-12-16 Pulverer, Gerhard, Prof. Dr.Dr.h.c. Use of specific monosaccharides for the preparation of a medicament for the prevention of metastases of malignic tumours
US4904596A (en) * 1985-08-07 1990-02-27 Fred Hutchinson Cancer Research Center Hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside
EP0380084A2 (en) * 1989-01-27 1990-08-01 The Biomembrane Institute Method for the inhibition of cell-cell and cell substratum interactions by the blocking of carbohydrate-carbohydrate interactions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3228233A1 (en) * 1982-07-28 1984-02-02 Wolfgang Dr. 6500 Mainz Dippold The use of the antibody R-24 and method for the inhibition of the cell growth of melanoma cells
US4904596A (en) * 1985-08-07 1990-02-27 Fred Hutchinson Cancer Research Center Hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside
EP0249008A2 (en) * 1986-05-09 1987-12-16 Pulverer, Gerhard, Prof. Dr.Dr.h.c. Use of specific monosaccharides for the preparation of a medicament for the prevention of metastases of malignic tumours
EP0380084A2 (en) * 1989-01-27 1990-08-01 The Biomembrane Institute Method for the inhibition of cell-cell and cell substratum interactions by the blocking of carbohydrate-carbohydrate interactions

Non-Patent Citations (33)

* Cited by examiner, † Cited by third party
Title
ANALYTICAL BIOCHEMISTRY, Vol. 131, 1983 Charles O. Beauchamp et al: "A New Procedure for the Synthesis of Polyethylene Glycol-Protein Adducts; Effects on Function, Receptor Recognition, and Clearance of Superoxide Dismutase, Lactoferrin, and alfa2-M", *
ANALYTICAL BIOCHEMISTRY, vol. 131, 1983; C.O. BEAUCHAMP et al., pp. 25-33/ *
CANCER COMMUNICATIONS, Vol. 2, No. 9, 1990 Hisao Oguchi et al: "Effect of Lactose Derivatives on Metastatic Potential of B16 Melanoma Cells ", *
CANCER COMMUNICATIONS, vol. 2, no. 9, 1990; H. OGUCHI et al., pp. 311-316/ *
CANCER RESEARCH, Vol. 46, July 1986 John G. Collard et al: "Cell Surface Sialic Acid and the Invasive and Metastatic Potential of T-Cell Hybridomas ", *
CANCER RESEARCH, vol. 46, July 1986; J.G. COLLARD et al., pp. 3521-3527/ *
CLIN.EXPL.METASTASIS, Vol. 6, No. 2, 1988 J. Beuth et al: "Inhibition of liver tumor cell colonization in two animal tumor models by lectin blocking with D-galactose or arabinogalactan ", *
CLINICAL EXPL. METASTASIS, vol. 6, no. 2, 1988; J. BEUTH et al., pp. 115-120/ *
DEVELOPMENTAL BIOLOGY, Vol. 122, 1987 Bruce A. Fenderson et al: "Glycolipid Core Structure Switching from Globo- to Lacto- and Ganglio-Series during Retinoic Acid-Induced Differentiation of TERA-2-Derived Human Embryonal Carcinoma Cells ", *
DEVELOPMENTAL BIOLOGY, vol. 122, 1987; B.A. FENDERSON et al., pp. 21-34/ *
Dialog Information Services, File 159, Cancerlit, Dialog accession no. 00575160, Iliopoulos D. et al: "Inhibition of metastases of a human melanoma xenograft by an anti-GD2/GD3 monoclonal antibody (meeting abstract)", Proc Annu Meet Am Assoc Cancer Res; 28:77 1987 *
DIALOG INFORMATION SERVICES, File 159, Medline 66-90/May, Medline AN 86255075; T. MORI et al., AN 00540856/ *
Dialog Information Services, File 159: Medline 66-90/May, accession no. 00540856, Medline accession no. 86255075, Mori T et al: "Heterophil forssman glycoprotein and adenovirus 12:transformed rat cell lines", & J Natl Cancer Inst; 77(1):115-20 1986 *
EXPERIMENTIA, Vol. 45, 1989 W. Roszkowski et al: "Blocking of lectin-like adhesion molecules on pulmonary cells inhibits lung sarcoma L-1 colonization in BALB/c-mice ", *
EXPERIMENTIA, vol. 45, 1989; W. ROSZKOWSKI et al., pp. 584-588/ *
J CANCER RES CLIN ONCOL, Vol. 113, 1987 J. Beuth et al: "Inhibition of liver metastasis in mice by blocking hepatocyte lectins with arabinogalactan infusions and D-galactose ", *
J. Nat. Cancer Inst., Vol. 71, No. 2, August 1983 Sen-itiroh Hakomori et al.: "Glycosphingolipids as Tumor-Associated and Differentiation Markers ", *
JOURNAL OF CANCER RESEARCH & CLINICAL ONCOLOGY, vol. 113, 1987; J. BEUTH et al., pp. 51-55/ *
JOURNAL OF CELL BIOLOGY, vol. 111, August 1990; I. CORNIL et al., pp. 773-781/ *
JOURNAL OF NATL. CANCER INST., vol. 71, no. 2, August 1983; H. SEN-ITIROH et al., pp. 231-251/ *
National Library of Medicine (NLM), File Medline, Medline accesion no. 90277512, Tsukada K: "Anti- metastatic and growth-inhibitory effects of N- acetylchitohexaose in mice bearing Lewis lung car- cinoma", Jpn J Cancer Res 1990 Mar; 81(3): 259-65 *
National Library of Medicine database, File Medline, NLM Accession no. 84106532, Dippold W.G. et al: "Inhibition of human melanoma cell growth in vitro by monoclonal anti-GD3- -gandlioside antibody", & Cancer Res 1984 Feb; 44(2):806-10 *
National Library of Medicine database, File Medline, NLM Accession no. 86277574, Katano M et al: "Human IgM monoclonal anti-GD2 antibody: reactivity to a human melanoma xenograft",& Jpn J Cancer Res 1986 Jun;77(6):584-94 *
National Library of Medicine database, File Medline, NLM Accession no. 87041518, Irie R.F. et al: "Regression of cutaneous meta- static melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2", & Proc Natl Acad Sci U S A 1986 Nov;83(22):8694-8 *
National Library of Medicine database, File Medline, NLM Accession no. 89141796, Iliopoulos D. et al: "Inhibition of metastases of a human melanoma xenograft by monoclonal antibody to the GD2/GD3 gangliosides", & J Natl Cancer Inst 1989 Mar 15; 81(6);440-4 *
National Library of Medicine database, File Medline, NLM Accession no. 90025151, Muramatsu T: "Glycoproteins associated with meta- static potential of cancer:", & Gan To Kagaku Ryoho 1989 Oct; 16(10):3354-8 *
National Library of Medicine database, File Medline, NLM Accession no. 90187481, Hamanaka S et al: "Strong anti-tumor effect of monosialoganglioside specific monoclonal antibody 202: a clinical trial in a cancer patient with melanoma", & J Dermatol 1989 Dec;16(6):480-6 *
NATL. LIBRARY OF MEDICINE DATABASE, File Medline; D. ILIOPOULOS et al., AN 89141796; and T. MURAMATSU, AN 90025151; and M. KATANO et al., AN 86277574; and R.F. IRIE et al., AN 87041518; and S. HAMANAKA et al., AN 90187481; and W.G. DIPPOLD et al., AN 84106532/ *
THE JOURNAL OF CELL BIOLOGY, Vol. 111, August 1990 Isabelle Cornil et al: "Tumor Cell Surface beta1-4-Linked Galactose Binds to Lectin(s) on Microvascular Endothelial Cells and Contributes to Organ Colonization ", *
ZBL. BAKT., vol. 274, 1990; J. BEUTH et al., pp. 350-358/ *
ZBL.BAKT., Vol. 274, 1990 J. Beuth et al: "Lectins: Mediators of Adhesion for Bacteria in Infections Diseases and for Tumor Cells in Metastasis ", *
ZEITSCHRIFT F~R NATURFORSCHUNG. Section C. Biosciences, Vol. 38, 1983 Enrico Boccu et al: "Coupling of Monomethoxypolyethyleneglycols to Proteins via Active Esters ", *
ZEITSCHRIFT FÜR NATURFORSCHUNG, Section C, Biosciences, vol. 38, 1983; E. BOCCU et al., pp. 94-99/ *

Also Published As

Publication number Publication date
AU8667791A (en) 1992-03-30
AU659808B2 (en) 1995-06-01
CA2089375A1 (en) 1992-03-01
EP0546122A1 (en) 1993-06-16
JPH06501008A (en) 1994-01-27
WO1992004048A2 (en) 1992-03-19

Similar Documents

Publication Publication Date Title
CA2218246A1 (en) Enzymatic synthesis of glycosidic linkages
IL125928A0 (en) Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and pharmaceutical compositions for inhibiting the same
AU3835285A (en) Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
FI935396L (en) Novel nanoparticle blood X-ray contrast agent compositions containing high molecular weight surfactant
EP1057862A3 (en) Polymer film compositions for capsules
NL191308C (en) Lyophilized post-solution injectable preparation containing an anthracycline glycoside and process for the preparation of an injectable solution of an anthracycline glycoside.
AU1378499A (en) Methods for treating prostate tumors using radioactive compositions
CA2066728A1 (en) Anti-tumor preparation comprising interleukin-2 and histamine, analogs thereof or h2-receptor agonists
HRP20020330B1 (en)
KR970061909A (en) Ginseng saponin intestinal bacterial metabolites and anti-cancer agents containing the same as active ingredients
ZA200202184B (en) Fucosylated oligosaccharides and process for their preparation.
WO1992018610A3 (en) Compositions and methods for endothelial binding
KR930007882A (en) Cytotoxic bicyclo [7.3.1] tride-4 sen-2,6diyne compounds and preparation methods thereof
AU2407899A (en) Monoclonal antibody which recognizes the oligosaccharide n-glycolylated-galactose-glucose sialic acid in malignant tumors, and composition containing it
WO1992004048A3 (en) Inhibition of metastasis potential and invasiveness by oligosaccharides or oligosaccharide antigens or antibodies
WO1997029199A3 (en) Prostate specific antigen peptides and uses thereof
CZ16395A3 (en) Inclusion complexes of nimesulid salts of alkali metals and alkaline earth metals with cyclodextrins, process of their preparation and pharmaceutical compositions containing thereof
BG100863A (en) Fibrin-specifil antibody and its use as an antithrombotic agent
MXPA02004942A (en) Use of anti idiotypical antibodies as vaccines against cancer.
BG103735A (en) Method for the preparation of substituted thiazolidindions
EP0490816A3 (en) Fluoro-compounds
FI834042A0 (en) NYA FIBRINOLYTISKA ENZYMER, FOERFARANDEN FOER FRAMSTAELLNING AV DEM OCH PHARMACEUTICAL PREPARAT INNEHAOLLANDE DEM
IE781659L (en) Pseudotrisaccharides
AU6182994A (en) Bifunctional glycoproteins having a modified carbohydrate complement, and their use in tumor-selective therapy
GR3023427T3 (en) Heteroarylmethylbenzols aromatase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 2089375

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1991919388

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1991919388

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1991919388

Country of ref document: EP